Browsed by
Tag: funds

Here is What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT)

Here is What Hedge Funds Think About Rocket Pharmaceuticals, Inc. (RCKT)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th, when the S&P 500 Index was trading around the 3100 level. Stocks kept going up since then. In this article we look at how hedge funds traded Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) and determine whether the smart money was really smart about this stock.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) was in 19 hedge funds’ portfolios at the end of June. The all time high for this statistics is 21. RCKT has seen an increase in hedge fund interest in recent months. There were 15 hedge funds in our database with RCKT positions at the end of the first quarter. Our calculations also showed that RCKT isn’t among the 30 most popular stocks among hedge funds (click for Q2 rankings and see the video for a quick look at the top 5 stocks). Video: Watch our video about the top 5 most popular hedge fund stocks.

In the financial world there are many signals stock market investors use to grade stocks. A duo of the less utilized signals are hedge fund and insider trading sentiment. Our researchers have shown that, historically, those who follow the best picks of the elite investment managers can trounce the market by a solid margin (see the details here).

Samuel Isaly Orbimed Advisors
Samuel Isaly Orbimed Advisors

Samuel Isaly of OrbiMed Advisors

At Insider Monkey we scour multiple sources to uncover the next great investment idea. For example, Federal Reserve has been creating trillions of

Read the rest
Hedge Funds Are Crazy About Xeris Pharmaceuticals, Inc. (XERS)

Hedge Funds Are Crazy About Xeris Pharmaceuticals, Inc. (XERS)

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of June 30th, when the S&P 500 Index was trading around the 3100 level. Since the end of March, investors decided to bet on the economic recovery and a stock market rebound. S&P 500 Index returned more than 50% since its bottom. In this article you are going to find out whether hedge funds thought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) was a good investment heading into the third quarter and how the stock traded in comparison to the top hedge fund picks.

Is Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) an attractive stock to buy now? Investors who are in the know were getting more bullish. The number of long hedge fund bets inched up by 10 in recent months. Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) was in 20 hedge funds’ portfolios at the end of June. The all time high for this statistics is 10. This means the bullish number of hedge fund positions in this stock currently sits at its all time high. Our calculations also showed that XERS isn’t among the 30 most popular stocks among hedge funds (click for Q2 rankings and see the video for a quick look at the top 5 stocks). Video: Watch our video about the top 5 most popular hedge fund stocks.

To the average investor there are a large number of methods stock market investors have at their disposal to analyze publicly traded companies. A pair of the most underrated methods are hedge fund and insider trading indicators. Our researchers have shown that, historically, those who follow the top picks of the top

Read the rest
Is Enanta Pharmaceuticals Inc (ENTA) Going to Burn These Hedge Funds?

Is Enanta Pharmaceuticals Inc (ENTA) Going to Burn These Hedge Funds?

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the second quarter. You can find articles about an individual hedge fund’s trades on numerous financial news websites. However, in this article we will take a look at their collective moves over the last 5 years and analyze what the smart money thinks of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) based on that data and determine whether they were really smart about the stock.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) was in 20 hedge funds’ portfolios at the end of the second quarter of 2020. The all time high for this statistics is 21. ENTA investors should be aware of an increase in hedge fund interest in recent months. There were 18 hedge funds in our database with ENTA positions at the end of the first quarter. Our calculations also showed that ENTA isn’t among the 30 most popular stocks among hedge funds (click for Q2 rankings and see the video for a quick look at the top 5 stocks). Video: Watch our video about the top 5 most popular hedge fund stocks.

In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey’s monthly stock picks returned 101% since March 2017 and outperformed the S&P 500 ETFs by more than 56 percentage points. Our short strategy outperformed the S&P 500 short ETFs by 20 percentage

Read the rest
Your Funds: Mailbag: It’s not too late for COVID financial relief | Column

Your Funds: Mailbag: It’s not too late for COVID financial relief | Column

The mailbag is full of notes from people with all-too-common financial dilemmas these days.

I’ll try to help some of the letter writers in the hope that the answers help you too.

Question from David H. in Short Pump: When I lost my job early in the pandemic, there seemed to be a lot of help out there from banks and credit card companies for people who were unemployed. But we didn’t need help then, because my wife was working for [a major airline].

She was part of the layoffs they just announced. I’m making money working on some projects, but it’s not enough. I don’t want to fall behind on the mortgage and the bills, but what can I say to my lenders now, so far into the pandemic, that they will help me, and why would they help me anyway if we have almost no income and don’t know when that will change?

Answer: Don’t worry about optics; push on.

Mortgage forbearance on federally backed mortgages was part of the CARES Act, the initial coronavirus stimulus package, and you should be able to pause mortgage payments for up to 12 months, in 180-day chunks, by contacting the lender about a virus hardship.

Generally speaking, lenders have shown a willingness to hold off on missed mortgage payments by adding them to the back end of the loan. Let’s say you have 12 years remaining on the loan, meaning it would be paid off in October 2032 if you don’t hit the brakes. If you pause payments for six months, you will still owe 12 years of payments and you will pay things off in the spring of 2033. That’s effectively like accessing your home equity to get you through trouble.

Source Article Read the rest

Hedge Funds Dipping Their Toes Into Ionis Pharmaceuticals, Inc. (IONS)

Hedge Funds Dipping Their Toes Into Ionis Pharmaceuticals, Inc. (IONS)

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not always available for the general crowd. This doesn’t mean that they don’t have occasional colossal losses; they do. However, it is still a good idea to keep an eye on hedge fund activity. With this in mind, let’s examine the smart money sentiment towards Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and determine whether hedge funds skillfully traded this stock.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) investors should be aware of an increase in hedge fund interest of late. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) was in 23 hedge funds’ portfolios at the end of June. The all time high for this statistics is 27. There were 22 hedge funds in our database with IONS holdings at the end of March. Our calculations also showed that IONS isn’t among the 30 most popular stocks among hedge funds (click for Q2 rankings and see the video for a quick look at the top 5 stocks). Video: Watch our video about the top 5 most popular hedge fund stocks.

So, why do we pay attention to hedge fund sentiment before making any investment decisions? Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 56 percentage points since March 2017 (see the details here). We

Read the rest